Teva Pharmaceuticals
By Sean Williams, The Motley Fool
| 1:15PM 8/24/2011
Chinese medicine postulates the existence of qi, a circulating life force whose properties must be balanced for optimal health. Take a page from eastern philosophy and consider investing in these pairings of complementary stocks to strengthen your portfolio.
| 10:10AM 6/30/2010
AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.
| 11:00AM 5/28/2010
An FDA "bioequivalent" certification doesn't exempt generic drugmakers from responsibility for their medication's safety, a judge has ruled. Teva Pharmaceuticals had been sued for the problems its version of antidepressant Wellbutrin has caused users.
| 9:30AM 1/14/2010
The Feds -- and consumers -- may finally have had it with 'pay-for-delay.' In these deals, generic drug companies that challenge a patent held by a name-brand pharmaceuticals agree to settle by delaying their entry into the market in return for a payment. But regulators are now calling for laws to end the practice.
| 4:40PM 12/01/2009
The case of Abbott Laboratories' (ABT) cholesterol drug TriCor is quite interesting. The drug has been a blockbuster, and it has been under patent protection for decades. That's right, decades. Now, Abbott has managed to seal a deal with generic-drug maker Teva Pharmaceuticals Industries (TEVA)...